Cargando…
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534204/ https://www.ncbi.nlm.nih.gov/pubmed/28756533 http://dx.doi.org/10.1007/s00395-017-0643-0 |
_version_ | 1783253737389686784 |
---|---|
author | Li, Wennan Chen, Xingjuan Riley, Ashley M. Hiett, S. Christopher Temm, Constance J. Beli, Eleni Long, Xin Chakraborty, Saikat Alloosh, Mouhamad White, Fletcher A. Grant, Maria B. Sturek, Michael Obukhov, Alexander G. |
author_facet | Li, Wennan Chen, Xingjuan Riley, Ashley M. Hiett, S. Christopher Temm, Constance J. Beli, Eleni Long, Xin Chakraborty, Saikat Alloosh, Mouhamad White, Fletcher A. Grant, Maria B. Sturek, Michael Obukhov, Alexander G. |
author_sort | Li, Wennan |
collection | PubMed |
description | Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pigs and determined whether long-term treatment with a mineralocorticoid receptor inhibitor, spironolactone, attenuates coronary TRPC expression and associated dysfunctions. MetS coronary arteries exhibited significant atherosclerosis, endothelial dysfunction, and increased histamine-induced contractions. Immunohistochemical studies revealed that TRPC6 immunostaining was significantly greater in the medial layer of MetS pig coronary arteries compared to that in Lean pigs, whereas little TRPC6 immunostaining was found in atheromas. Conversely, TRPC1 immunostaining was weak in the medial layer but strong in MetS atheromas, where it was predominantly localized to macrophages. Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs. In vivo targeted delivery of the dominant-negative (DN)-TRPC6 cDNA to the coronary wall reduced histamine-induced calcium transients in the MetS coronary artery medial layer, implying a role for TRPC6 in mediating calcium influx in MetS coronary smooth muscles. Monocyte adhesion was increased in Lean pig coronary arteries cultured in the presence of aldosterone; and spironolactone antagonized this effect, suggesting that coronary mineralocorticoid receptor activation may regulate macrophage infiltration. TRPC1 expression in atheroma macrophages was associated with advanced atherosclerosis, whereas medial TRPC6 upregulation correlated with increased histamine-induced calcium transients and coronary contractility. We propose that long-term spironolactone treatment may be a therapeutic strategy to decrease TRPC expression and coronary pathology associated with MetS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-017-0643-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5534204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-55342042017-08-14 Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs Li, Wennan Chen, Xingjuan Riley, Ashley M. Hiett, S. Christopher Temm, Constance J. Beli, Eleni Long, Xin Chakraborty, Saikat Alloosh, Mouhamad White, Fletcher A. Grant, Maria B. Sturek, Michael Obukhov, Alexander G. Basic Res Cardiol Original Contribution Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pigs and determined whether long-term treatment with a mineralocorticoid receptor inhibitor, spironolactone, attenuates coronary TRPC expression and associated dysfunctions. MetS coronary arteries exhibited significant atherosclerosis, endothelial dysfunction, and increased histamine-induced contractions. Immunohistochemical studies revealed that TRPC6 immunostaining was significantly greater in the medial layer of MetS pig coronary arteries compared to that in Lean pigs, whereas little TRPC6 immunostaining was found in atheromas. Conversely, TRPC1 immunostaining was weak in the medial layer but strong in MetS atheromas, where it was predominantly localized to macrophages. Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs. In vivo targeted delivery of the dominant-negative (DN)-TRPC6 cDNA to the coronary wall reduced histamine-induced calcium transients in the MetS coronary artery medial layer, implying a role for TRPC6 in mediating calcium influx in MetS coronary smooth muscles. Monocyte adhesion was increased in Lean pig coronary arteries cultured in the presence of aldosterone; and spironolactone antagonized this effect, suggesting that coronary mineralocorticoid receptor activation may regulate macrophage infiltration. TRPC1 expression in atheroma macrophages was associated with advanced atherosclerosis, whereas medial TRPC6 upregulation correlated with increased histamine-induced calcium transients and coronary contractility. We propose that long-term spironolactone treatment may be a therapeutic strategy to decrease TRPC expression and coronary pathology associated with MetS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-017-0643-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-07-29 2017 /pmc/articles/PMC5534204/ /pubmed/28756533 http://dx.doi.org/10.1007/s00395-017-0643-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Contribution Li, Wennan Chen, Xingjuan Riley, Ashley M. Hiett, S. Christopher Temm, Constance J. Beli, Eleni Long, Xin Chakraborty, Saikat Alloosh, Mouhamad White, Fletcher A. Grant, Maria B. Sturek, Michael Obukhov, Alexander G. Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title_full | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title_fullStr | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title_full_unstemmed | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title_short | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
title_sort | long-term spironolactone treatment reduces coronary trpc expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534204/ https://www.ncbi.nlm.nih.gov/pubmed/28756533 http://dx.doi.org/10.1007/s00395-017-0643-0 |
work_keys_str_mv | AT liwennan longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT chenxingjuan longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT rileyashleym longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT hiettschristopher longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT temmconstancej longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT belieleni longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT longxin longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT chakrabortysaikat longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT allooshmouhamad longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT whitefletchera longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT grantmariab longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT sturekmichael longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs AT obukhovalexanderg longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs |